ClinicalTrials.gg

Program

retavibart

Its studies are mostly in Respiratory Syncytial Virus Infections, led by Zhuhai Trinomab Pharmaceutical.

Furthest: phase 3, since Sep 10, 20233 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zhuhai Trinomab Pharmaceutical30 open or runningphase 3since Sep 10, 2023Nov 9, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2022First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT05630573 · 31 enrolled · China
  2. Sep 10, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06083623 · 2,282 enrolled · China
  3. Nov 26, 2024Phase 3 study in Respiratory Syncytial Virus InfectionsNCT06710925 · 315 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06710925Respiratory Syncytial Virus Infections · China3CompletedJul 27, 2025315
NCT06083623Respiratory Syncytial Virus Infections · China3CompletedJun 16, 20252,282
NCT05630573Respiratory Syncytial Virus Infections · China2CompletedJun 30, 202331

How it is read

Names in the registry

  • “TNM001”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
retavibart (Zhuhai Trinomab Pharmaceutical): development program | ClinicalTrials.gg